Prognostic and diagnostic utility of interleukin-6 in pediatric pulmonary arterial hypertension - a case-control study.
Diagnostic
Interleukin-6
Prognostic
Pulmonary arterial hypertension
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
09 Jan 2024
09 Jan 2024
Historique:
received:
14
08
2023
accepted:
26
12
2023
revised:
23
11
2023
medline:
9
1
2024
pubmed:
9
1
2024
entrez:
9
1
2024
Statut:
aheadofprint
Résumé
Pulmonary arterial hypertension (PAH) in pediatrics is a progressive disease with significant vascular remodeling, right sided heart failure, and death if left untreated. Elevated interleukin-6 (IL-6) level in PAH patients is taken as an independent predictor of adverse outcome including mortality. The aim of this study was to investigate and compare serum levels of IL-6 in children with PAH and healthy matched controls, and correlate between IL-6 and degree of PAH, as well as mortality. IL-6 was measured by ELISA in serum samples in 40 children with PAH (age 1-12 years) and 40 age and sex-matched healthy controls. There was a statistically significant increase in IL-6 level among PAH cases compared with the controls (1.85 ng/L vs 1.30 ng/L, p-value = 0.004). IL-6 at cut off point 1.45 ng/L significantly predict pulmonary hypertension in children (AUC = 0.685, 75% sensitivity, and 65% specificity with p = 0.002). There was no statistically significant association between IL-6 level and degree of PAH (p = 0.218). There was no statistically significant association between IL-6 level and mortality (p = 0.662). Conclusion: IL-6 significantly predict PAH in pediatrics but there is no association between IL-6 level and degree of PAH or mortality. IL-6 may provide a less costly and less invasive method for disease detection. What is Known: • Definitive diagnosis of PAH is made by right heart catheterization, while echocardiography is the gold standard for tracking the course of the disease. What is New: • It was assumed that children with a diagnosis of PAH would have higher serum IL-6 levels than controls. Furthermore, an adverse relationship between the blood IL-6 level and PPAH was predicted.
Identifiants
pubmed: 38193997
doi: 10.1007/s00431-023-05413-2
pii: 10.1007/s00431-023-05413-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Galiè N, McLaughlin VV, Rubin LJ, Simonneau G (2019) An overview of the 6th world symposium on pulmonary hypertension. Eur Respir J 53(1):1802148
doi: 10.1183/13993003.02148-2018
pubmed: 30552088
pmcid: 6351332
Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RB (2019) Pediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J 53(1):1801916. https://doi.org/10.1183/13993003.01916-2018
doi: 10.1183/13993003.01916-2018
pubmed: 30545978
pmcid: 6351335
Del Cerro M, Abman S, Diaz G, Freudenthal A, Freudenthal F, Harikrishnan S, Haworth S, Ivy D, Lopes A, Raj J, Sandoval J, Stenmark K, Adatia I (2011) A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011. Pulm Circ 1(2):286–298
doi: 10.4103/2045-8932.83456
pubmed: 21874158
pmcid: 3161725
Ivy D (2016) Pulmonary hypertension in children. Cardiol Clin 34(3):451–472
doi: 10.1016/j.ccl.2016.04.005
pubmed: 27443141
pmcid: 4959130
Rafikova O, Imad A, Ruslan R (2019) Focus on early events: pathogenesis of pulmonary arterial hypertension development. Antioxid Redox Signal 31(13):933–953
doi: 10.1089/ars.2018.7673
pubmed: 31169021
pmcid: 6765063
O'Byrne ML, Kennedy KF, Kanter JP, Berger JT, Glatz AC (2018) Risk factors for major early adverse events related to cardiac catheterization in children and young adults with pulmonary hypertension: an analysis of data from the IMPACT (Improving Adult and Congenital Treatment) registry. J Am Heart Assoc 7.5:e008142
Cappelleri JC, Hwang LJ, Mardekian J, Mychaskiw MA (2010) PCV138 Measurement properties of peak VO2 in children with pulmonary arterial hypertension. Value Health 7.13:A367
Erzurum S, Rounds S, Stevens T, Aldred M (2010) Strategic plan for lung vascular research: an NHLBI-ORDR workshop report. Am J Respir Crit Care Med 182.12:1554–1562
Dereddy N (2012) Associated inflammation or increased flow-mediated shear stress, but not pressure alone, disrupts endothelial caveolin-1 in infants with pulmonary hypertension. Pulm Circ 2(4):492–500
doi: 10.4103/2045-8932.105038
pubmed: 23372934
pmcid: 3555420
Morice A (1990) Atrial natriuretic peptide in primary pulmonary hypertension. Eur Respir J 3(8):910–913
doi: 10.1183/09031936.93.03080910
pubmed: 2149841
Hall S (2009) Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. Thorax 64(9):778–783
doi: 10.1136/thx.2008.106435
pubmed: 19525266
Kishimoto T (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23:1
doi: 10.1146/annurev.immunol.23.021704.115806
pubmed: 15771564
Duncan M, Wagner BD, Murray K, Allen J, Colvin K, Accurso FJ, Ivy DD (2012) Circulating cytokines and growth factors in pediatric pulmonary hypertension. Mediators Inflamm 2012 Article ID 143428. https://doi.org/10.1155/2012/143428
Tanaka T, Masashi N, Tadamitsu K (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):a016295
doi: 10.1101/cshperspect.a016295
pubmed: 25190079
pmcid: 4176007
Hansmann G, Koestenberger M, Alastalo TP, Apitz C, Austin ED, Bonnet D, Budts W, D’Alto M, Gatzoulis M, Hasan B (2019) ‘2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT. J Heart Lung Transplant 38(9):879–901
doi: 10.1016/j.healun.2019.06.022
pubmed: 31495407
Hasan B, Hansmann G, Budts W, Heath A, Hoodbhoy Z, Jing ZC, Koestenberger M, Meinel K, Mocumbi A, Radchenko G (2020) Sallmon N Challenges and special aspects of pulmonary hypertension in middle-to low-income regions: JACC state-of-the-art review. J Am Coll Cardiol 75(19):2463–2477
doi: 10.1016/j.jacc.2020.03.047
pubmed: 32408981
Robbins I, Moore T, Blaisdell C, Abman S (2012) Improving outcomes for pulmonary vascular disease. Am J Respir Crit Care Med 185(9):1015–1020
doi: 10.1164/rccm.201201-0049WS
pubmed: 22335936
pmcid: 3359939
Chen J (2020) Elevated interleukin-6 levels predict clinical worsening in pediatric pulmonary arterial hypertension. J Pediatr 223:164–169
doi: 10.1016/j.jpeds.2020.04.041
pubmed: 32711743
pmcid: 7388069
Ezekian JE, Hill KD (2019) Management of pulmonary arterial hypertension in the pediatric patient. Curr Cardiol Rep 21(12):1–11
doi: 10.1007/s11886-019-1229-2
Oz-Tuncer G (2017) The role of inflammatory biomarkers in CHD-associated pulmonary hypertension in children. Cardiol Young 27(2):255–260
doi: 10.1017/S1047951116000408
pubmed: 28366184
Selimovic N (2009) Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 34(3):662–668
doi: 10.1183/09031936.00174908
pubmed: 19324949
Humbert M (1995) Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151(5):1628–1631
doi: 10.1164/ajrccm.151.5.7735624
pubmed: 7735624
Koudstaal T (2021) Plasma markers in pulmonary hypertension subgroups correlate with patient survival. Respir Res 22(1):1–13
doi: 10.1186/s12931-021-01716-w
Hoeper MM, Welte T (2007) Systemic inflammation, COPD, and pulmonary hypertension. Chest 131(2):634–635
doi: 10.1378/chest.06-2207
pubmed: 17296674
Prins W (2018) Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. J Heart Lung Transplant 37(3):376–384
doi: 10.1016/j.healun.2017.08.011
pubmed: 28893516
Soon E, Holmes A, Treacy C, Doughty N, Southgate L, Machado R, Trembath R, Jenning S, Barker L, Nicklin P, Walker C, Budd D, Pepke-Zaba J, Morrell N (2010) Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122(9):920–927
doi: 10.1161/CIRCULATIONAHA.109.933762
pubmed: 20713898
Steiner M (2009) Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104(2):236–244
doi: 10.1161/CIRCRESAHA.108.182014
pubmed: 19074475
Cracowski J (2014) Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J 43(3):915–917
doi: 10.1183/09031936.00151313
pubmed: 24232704
Heresi G, Aytekin M, Hammel J, Wang S, Chatterjee S (2014) Dweik R Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension. Eur Respir J 43(3):912–914
doi: 10.1183/09031936.00164713
pubmed: 24136333